WY60.F INIFY LABORATORIES AB

Healthcare Biotechnology Frankfurt Exchange
0.3780 EUR
Close of Nov 12, 2026
0.1380 0.8000
Market cap
EUR 40.6M
P/E
-
P/B
3.26x
ROE
-59.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is WY60.F undervalued?

Graham number

The Graham number of INIFY LABORATORIES AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

INIFY LABORATORIES AB fundamental analysis

No fundamental analysis for INIFY LABORATORIES AB yet.

INIFY LABORATORIES AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About INIFY LABORATORIES AB

INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.

Full company profile